US FDA recalls Covid-19 at-home tests by SD Biosensor over bacteria risks

The US Food and Drug Administration has issued a warning to consumers and health providers to discontinue using and discard recalled Pilot COVID-19 At-Home Tests made by SD Biosensor

coronavirus
Photo: Bloomberg
ANI US
2 min read Last Updated : May 07 2023 | 8:03 AM IST

The US Food and Drug Administration has issued a warning to consumers and health providers to discontinue using and discard recalled Pilot COVID-19 At-Home Tests made by SD Biosensor, Inc, CNN reported. The US FDA stated that the decision was taken over "significant concerns" of bacterial contamination.

SD Biosensor is recalling all impacted tests, which were distributed by Roche Diagnostics to various retailers to stop the spread of COVID-19 cases. The US FDA asked people to throw out any pilot tests from the affected lot numbers and do not pour the liquid solution down the drain.

The US FDA in the statement said, "The U.S. Food and Drug Administration (FDA) is warning consumers and health care providers to stop using and throw out certain lots of recalled SD Biosensor, Inc. Pilot COVID-19 At-Home Tests, distributed by Roche Diagnostics."

It further said, "The FDA has significant concerns of bacterial contamination in the Pilot COVID-19 At-Home Test liquid solution, provided in the test kit. Direct contact with the contaminated liquid solution may pose safety concerns and the bacterial contamination could impact the performance of the test."

The US FDA in the statement noted that approximately 500,000 tests were distributed to CVS Health and 16,000 tests to Amazon. According to the statement, the FDA is working with Roche Diagnostics to determine how many of those tests were sold to people.

The US FDA in the statement said, "If you received your tests through the COVID.gov/tests distribution or as part of other federal testing programs, they are not subject to this safety communication or product recall.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :coronaCoronavirus Tests

First Published: May 07 2023 | 8:03 AM IST

Next Story